Proteome Sciences is a CRO specializing in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterize proteins and their associated post-translational modifications. By using LC-MS2, SysQuant®, and TMTcalibratorTM methodologies we can detect up to 8,000 of proteins/sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up- or down-regulated with disease progression or drug treatment.
Quanterix™ Corporation is digitizing biomarker analysis with the goal of advancing the science of precision healthcare. Our ultra-sensitive technology platform, Simoa®, enables researchers to quantify a range of disease biomarkers at lower levels than ever before, in most common sample types. Simoa’s ultra-sensitivity, multiplex detection capability and flexibility in custom assay development are advancing both academic research and drug development both in our customers' own facilities and by contract in our CLIA-certified Quanterix Accelerator Laboratory.
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases are diagnosed and treated. Learn more: adaptivebiotech.com.
Tissue Solutions provides high-quality human biospecimens for drug discovery and diagnostics development. We work with an ethically compliant network of more than 200 sources worldwide and specialize in sourcing biological material linked to extremely detailed clinical data. The types of sample we can offer includes fresh, FFPE and flash frozen tissue. We also offer a diverse portfolio of biofluids including full apheresis collections, whole blood, serum and plasma and derived primary cells.
Swedish company Olink Proteomics provides the most efficient tool available for targeted human protein biomarker discovery, development and implementation, with high-throughput analysis, exceptional data quality, and minimal sample consumption. Disease or biological process-focused panels are available, with full transparency on our rigorous validation data. The current library enables rapid analysis of over 1,000 validated protein biomarkers with less than 15 µl of sample. Olink panels are available via our Analysis Service or as kits.
Invivoscribe® is a comprehensive CDx partner, providing ISO 13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. It offers internationally standardized testing through ISO 15189 laboratory network (US, Europe, Asia). Its Streamlined CDx™ model has proven successful in accelerating FDA, EMA and PMDA approvals of new targeted therapies.
Intertek’s GLP/GCP/GMP compliant laboratories provide support to clients focused on the development of pharmaceuticals and biologics. Our biomarker services provide both fit-for-purpose validations in support of exploratory biomarkers and full validation for biomarkers used as a companion diagnostic. Drug efficacy and safety profiling is performed using an array of platforms including ultra-sensitive ELISA, flow cytometry, cell-based assays and ECL multiplex platforms as well as provision of immunogenicity bioanalysis for pre-clinical and clinical studies.
Myriad RBM, Inc. is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
Mursla is a Cambridge-based liquid biopsy startup developing a proprietary novel platform for cancer detection. Its unique nanosensing technology can selectively detect a wide range of biomarkers within minutes at low concentrations from fresh blood samples. It is currently focused on the isolation and detection of surface exosomal proteins secreted by cancer cells as well as tumour autoantibodies.